Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
| Autor: | Ulf Lützen, Marlies Marx, Michael Jüptner, Maaz Zuhayra |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Leiomyosarcoma
177Lu-PSMA-617 Lutetium urologic and male genital diseases Ligands 03 medical and health sciences Prostate cancer Heterocyclic Compounds 1-Ring 0302 clinical medicine Female patient Radioligand medicine Humans Radiology Nuclear Medicine and imaging In patient Neoplasm Metastasis business.industry Soft tissue General Medicine Dipeptides Middle Aged Prostate-Specific Antigen medicine.disease 030220 oncology & carcinogenesis Radionuclide therapy Cancer research Female business 030217 neurology & neurosurgery |
| Zdroj: | Nuklearmedizin. Nuclear medicine. 58(4) |
| ISSN: | 2567-6407 |
| Popis: | IntroductionSystemic radionuclide therapy with 177Lu-PSMA-617 is a novel treatment option in patients with metastasized and castration-resistant prostate cancer 4. The molecular target of the 177Lu-PSMA-617 radioligand therapy is the prostate-specific membrane antigen (PSMA) highly expressed on prostate cancer cells. Beyond the enhanced a ccumulation of PSMA on prostate cancer cells, PSMA expression is also found on the molecular surface or in the tumor-associated neovasculature of various tumor tissues including sarcomas of the soft tissue 2. Thus, PSMA has theoretically been discussed as a possible future target for systemic radioligand therapy with 177Lu-PSMA-617 even in non-prostate malignancies 1.Here we report on a female patient with extended metastasized leiomyosarcoma experimentally treated with one application of 177Lu-PSMA-617 radioligand therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|